- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03223675
Neurocognitive Impact and Dose-Effect Relationship of Hippocampal Avoidance During Whole Brain Radiotherapy Plus Simultaneous Integrated Boost - A Prospective Follow-up Study
April 27, 2023 updated by: Chang Gung Memorial Hospital
For newly-diagnosed patients with brain metastasis, whole brain radiation therapy (WBRT) probably remains a common palliative management even for those with oligometastatic brain disease.
However, WBRT-related late sequelae, particularly a decline in neurocognitive functions (NCFs), are a major concern.
More importantly, in patients with limited brain metastases and a fair/good performance status, sparing the radiosensitive and vulnerable structures which are responsible for essential NCFs during the WBRT course is one of the reasonable strategies to postpone and prevent the development of WBRT-induced neurocognitive impairments.
Actually, radiation-related neurocognitive dysfunction is usually characterized as a decline involving learning and memory, in which the extremely radiosensitive hippocampus indeed plays a critical role.
In addition to the neurocognitive preservation by virtue of sparing the radiosensitive structures like the hippocampus, durable intracranial tumor control critically depends on an escalated radiotherapeutic dose level which is adequate enough to eradicate gross metastatic brain lesions.
Therefore, in order to achieve both hippocampal sparing and simultaneous integrated boost(s) to gross metastatic foci, a specialized WBRT technique, hippocampal avoidance during WBRT plus simultaneous integrated boost (SIB) will be adopted in this prospective study.
Moreover, the dose-effect relationship would be analyzed in order to explore the correlation between the equivalent uniform dose (EUD) irradiating the hippocampus and the neurocognitive change/decline after the above WBRT course measured by objective neurocognitive test tools.
Newly-diagnosed cancer patients harboring 1-3 gross metastatic lesions but still in fair/good performance statuses are potentially eligible.
All recruited patients should receive baseline functional brain MRI examination and baseline neurobehavioral assessment.
Treatment planning will be designed via the technique of volumetric-modulated arc therapy (VMAT) to achieve both hippocampal avoidance and simultaneous integrated boost(s) to gross metastatic lesions.
Except for the above regions for which conformal avoidance or SIB is attempted, the prescribed dose to the remaining brain parenchyma will be consistently 3000 cGy in 12 fractions.
Accordingly, a battery of neuropsychological measures, which includes 7 standardized neuropsychological tests (e.g., executive functions, verbal and non-verbal memory, working memory, and psychomotor speed), is used to evaluate neurobehavioral functions for our registered patients.
The primary outcome measure is delayed recall, as determined by the change/decline in verbal memory or non-verbal memory, from the baseline assessment to 4 months after the start of the WBRT course.
This prospective cohort study aims to examine thoroughly the impact of a specialized WBRT technique, integrating both simultaneous integrated boost(s) delivered to gross metastatic foci and conformal hippocampal avoidance, on the status of NCF change/decline in patients with oligometastatic brain disease.
It is anticipated that intracranial local control will be more sustainable and durable resulting from the escalated focal dose of SIBs.
Ultimately, we also expect the dose-effect relationship will be clearly demonstrated after investigating the correlation between the hippocampal dosimetry and the status of NCF change/decline after receiving HA-WBRT plus SIB.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Taoyuan, Taiwan, 333
- Recruiting
- Chang Gung Memorial Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 84 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients with pathologically-confirmed non-hematopoietic malignancy who are referred for therapeutic or prophylactic WBRT
- Good performance status no worse than Eastern Cooperative Group (ECOG) of 2 or a general status of Karnofsky Score (KPS) at least 70 %
- The number and extent of brain metastatic lesions should be no more than three metastatic foci with a greatest diameter no more than 3 cm
Exclusion Criteria:
- Patients with MRI-identified metastasis within 5 mm perihippocampally
- Patients with metastasis involving the brain stem
- Clinical suspicion of leptomeningeal spreading
- Patients with a solitary brain metastatic lesion which had been totally removed
- History of prior radiotherapy including stereotactic radiosurgery delivered to brain/head region for any reasons
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Hippocampus-sparing WBRT plus SIB
All studied patients should undergo a computed tomography (CT) simulation scan encompassing the entire head region with 1.25-mm slice thickness using a thermoplastic mask for immobilization.
To achieve conformal hippocampal sparing during the delivery of whole brain radiation (WBRT) and simultaneous integrated boost(s) (SIB), the technique of volumetric modulated arc therapy (VMAT) via Linac-based RapidArc®.In terms of dose prescription, a dose of 30 Gy in 12 fractions was prescribed to whole-brain planning target volume (PTV) containing the normal brain parenchyma; an simultaneous integrated boost up to 120 - 150% is attempted to irradiate the gross metastatic foci.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary endpoint is delayed recall, as determined by the change/decline in verbal memory (WMS III- Word List score) from the baseline assessment to 4 months after the start of HS-WBRT.
Time Frame: 4 months after the start of HS-WBRT
|
Neurocognitive assessment: including memory, executive functions, and psychomotor speed.
This neurocognitive outcome was delayed recall, as determined by the change/decline in verbal memory [Wechsler Memory Scale - 3rd edition (WMS III) - Word List score] from the baseline assessment to 4 months after the start of the course of WBRT with hippocampus sparing (HS-WBRT).
Additionally, the follow-up of neurocognitive assessment will also be administered at 12 months and up to 18 months after the start of HS-WBRT
|
4 months after the start of HS-WBRT
|
The primary endpoint is delayed recall, as determined by the change/decline in non-verbal memory (WMS III- Visual Reproduction score) from the baseline assessment to 4 months after the start of HS-WBRT
Time Frame: 4 months after the start of HS-WBRT
|
Neurocognitive assessment: including memory, executive functions, and psychomotor speed.
This neurocognitive outcome was delayed recall, as determined by the change/decline in non-verbal memory (WMS III- Visual Reproduction score) from the baseline assessment to 4 months after the start of the course of WBRT with hippocampus sparing (HS-WBRT).
Additionally, the follow-up of neurocognitive assessment will also be administered at 12 months and up to 18 months after the start of HS-WBRT.
|
4 months after the start of HS-WBRT
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival time, indicated by the time from the date of recruitment to the date of expiring
Time Frame: up to 18 months
|
up to 18 months
|
The time from the date of recruitment to that of intracranial progression/failure noted on brain MRI or CT
Time Frame: up to 18 months
|
up to 18 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2016
Primary Completion (Anticipated)
December 31, 2025
Study Completion (Anticipated)
December 31, 2025
Study Registration Dates
First Submitted
June 22, 2017
First Submitted That Met QC Criteria
July 18, 2017
First Posted (Actual)
July 21, 2017
Study Record Updates
Last Update Posted (Actual)
May 1, 2023
Last Update Submitted That Met QC Criteria
April 27, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 104-9176A3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Metastasis
-
UNC Lineberger Comprehensive Cancer CenterWithdrawnBrain Metastasis | Brain Metastases | Brain LesionsUnited States
-
Instituto Nacional de Cancerologia de MexicoTerminatedBrain MetastasisMexico
-
National Taiwan University HospitalTerminated
-
Hokkaido University HospitalCompletedBrain MetastasisJapan
-
Chang Gung Memorial HospitalRecruitingBrain Metastasis | Brain MetastasesTaiwan
-
Centre Francois Baclesse, LuxembourgActive, not recruiting
-
Yale UniversityTerminatedBrain MetastasisUnited States
-
Institut de Cancérologie de LorraineCompleted
-
Main Line HealthCompletedBrain MetastasisUnited States
-
University of CincinnatiCompletedBrain MetastasisUnited States
Clinical Trials on hippocampal-sparing WBRT
-
Chang Gung Memorial HospitalRecruitingBrain Metastasis | Brain MetastasesTaiwan
-
Chang Gung Memorial HospitalRecruitingBrain Metastasis | Non-Small-Cell Lung Cancer (NSCLC)Taiwan
-
National Taiwan University HospitalUnknownMetastatic Malignant Neoplasm to BrainTaiwan
-
UNC Lineberger Comprehensive Cancer CenterUniversity of Michigan; Wake Forest University Health Sciences; University of...Completed
-
Sidney Kimmel Comprehensive Cancer Center at Johns...CompletedSCLC | Small-cell Lung Cancer | Small Cell Lung Cancer Limited StageUnited States
-
University of Erlangen-Nürnberg Medical SchoolUnknownRadiation of Neurocranial RegionGermany
-
Ottawa Hospital Research InstituteNot yet recruitingBrain Metastases | Radiosurgery
-
University College, LondonCancer Research UK; The Brain Tumour CharityCompletedBrain MetastasesUnited Kingdom
-
Samsung Medical CenterKorean Radiation Oncology GroupUnknownBrain MetastasesKorea, Republic of
-
National Taiwan University HospitalRecruitingMetastatic Malignant Neoplasm to BrainTaiwan